Magnesium sulfate added to standard therapy for acute organophosphate poisoning
Official title: Comparison of the Efficacy of Adjunctive Magnesium Sulphate With Standard Atropine and Pralidoxime Therapy vs Standard Therapy Alone in Acute Organophosphate Poisoning
Run by RESnTEC, Institute of Research · NCT07777835 · Data updated 2026-11-12
This study tests whether adding magnesium sulfate to standard treatment helps people with organophosphate poisoning see better outcomes.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 50 Years |
| Sex | All |
| Enrollment | 38 (estimated) |
| Sponsor | RESnTEC, Institute of Research Academic / other |
| Locations | 1 site (Multan, Punjab Province) |
| Status | Recruiting |
| Started | May 10, 2026 |
| Main results expected | October 10, 2026 |
| Study ends | October 10, 2026 |
| Registry record updated | August 20, 2026 |
| Trial ID | NCT07777835 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–50 with confirmed oral organophosphate poisoning who can provide informed consent (or via a legal representative).
✕Probably not a fit
Patients with magnesium intolerance, renal or cardiac impairments, pregnancy, lactation, or those presenting after two hours from arrival may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The trial compares adjunctive magnesium sulfate plus standard atropine-pralidoxime therapy versus standard therapy alone in adults with confirmed acute organophosphate poisoning. It aims to see if magnesium reduces 15-day mortality and lowers total atropine needs during hospitalization. The study also considers effects on respiratory complications, hospital stay, and ventilator use. Conducted in Multan, Pakistan, the investigation focuses on the potential benefits of a readily available adjunct in a resource-limited setting. The design evaluates safety and potential clinical impact in a real-world context.
Why it matters
Potential benefit: If successful, patients may experience lower mortality and reduced need for high-dose atropine and ventilatory support.
How similar studies have gone: Prior research suggests potential benefits of magnesium as an adjunct in OP poisoning, but evidence remains limited and context-dependent.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Both genders * Adult patients aged between 18 and 50 years * Confirmed clinical diagnosis of organophosphate poisoning containing insecticide, through the oral route * Adult patients, or their legally authorized representative, who will provide informed consent to participate in the study Exclusion Criteria: * Patients with known allergy to MgSO4 * Patients with documented pre-existing renal impairment (Serum creatinine more than 1.5mg/dl) * Patients with documented pre-existing cardiac impairments (e.g., heart block) * Pregnant or lactating women * Confirmed intake of any other drug or poison * Patients who will be declared dead on arrival or those who expired within 2 hours of presentation
Where it's running
-
Nishtar Hospital/Medical University
Multan, Punjab Province, Pakistan Recruiting
Study contacts
- Principal investigator: Sana Usman — Nishtar Hospital Multan, Pakistan
- Study coordinator: Sana Usman
- Email: sunusman0@gmail.com
- Phone: +923007154668
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.